Volume 14 Issue 4
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2023  >  14(4): 570-577
Shen Ze, Tian Yangyang, Zhou Zheng, et al. Clinical and epidemiological features analysis of pneumocystis jirovecii pneumonia in kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2023, 14(4): 570-577. doi: 10.3969/j.issn.1674-7445.2023.04.014
Citation: Shen Ze, Tian Yangyang, Zhou Zheng, et al. Clinical and epidemiological features analysis of pneumocystis jirovecii pneumonia in kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2023, 14(4): 570-577. doi: 10.3969/j.issn.1674-7445.2023.04.014
shu

Clinical and epidemiological features analysis of pneumocystis jirovecii pneumonia in kidney transplant recipients

doi: 10.3969/j.issn.1674-7445.2023.04.014

  • Department of Urology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China

More Information
  • Corresponding author: Hu Linkun, Email: hulinkunsz@163.com
  • Received Date: 2023-02-17
    Available Online: 2023-07-13
  • Publish Date: 2023-07-15
    Abstract
  •   Objective  To investigate clinical and epidemiological features of pneumocystis jirovecii pneumonia (PJP) in kidney transplant recipients.  Methods  Clinical data of 68 kidney transplant recipients admitted from July, 2021 to December, 2021 were collected. All patients were divided into the PJP group (n=11), common pulmonary infection group (n=24) and non-pneumonia group (n=33) according to the status of pulmonary infection. The incidence and treatment of PJP after kidney transplantation were analyzed. Basic characteristics and laboratory parameters of the recipients were compared among all groups. The genotyping and transmission map of PJP patients were evaluated.  Results  Among 64 kidney transplant recipients, 11 cases were definitely diagnosed with PJP. The most common clinical manifestations included elevated body temperature, and dry cough complicated with progressive dyspnea. Chest CT scan showed diffuse interstitial inflammation and ground glass-like lesions of bilateral lungs in all patients. After diagnosis, all patients were orally given with compound sulfamethoxazole for 3-4 weeks. Two patients received non-invasive ventilator-assisted ventilation due to severe lung infection and dyspnea, and the remaining patients were given with nasal cannula oxygenation. One patient experienced elevated serum creatinine level upon discharge, and developed renal allograft failure. The remaining 10 recipients with PJP obtained normal renal allograft function, and no recipient died. Compared with the non-pneumonia group, the rejection rate was higher, the length of hospital stay was longer, the lymphocyte count was less, the lymphocyte proportion was lower, the levels of C-reactive protein, serum creatinine and lactate dehydrogenase were higher, and the levels of serum albumin was lower and CD4+T cell count was less in the PJP group (all P < 0.05). Compared with common pulmonary infection group, the lymphocyte count was less, the lymphocyte proportion was lower, the CD4+T cell count was less and 1, 3-β-D- glucan (BDG) level was higher in the PJP group (all P < 0.05). No new genotype was detected in 10 of the 12 testing samples. It was considered that PJP mainly depended on two transmission chains and two independent transmission individuals.  Conclusions  Kidney transplant recipients are prone to pneumocystis jirovecii (PJ) infection due to impaired cellular immune function. The most common clinical manifestations consist of elevated body temperature and dry cough complicated with progressive dyspnea, accompanied by headache and fatigue in partial patients. Chest CT scan shows diffuse interstitial inflammation and ground glass-like lesion of bilateral lungs. PJ may be transmitted through respiratory tract. Small-scale PJP might occur in the follow-up outpatient of kidney transplant recipients. Preventive measures should be delivered in a timely manner.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    HOSSEINI-MOGHADDAM SM, OUÉDRAOGO A, NAYLOR KL, et al. Incidence and outcomes of invasive fungal infection among solid organ transplant recipients: a population-based cohort study[J]. Transpl Infect Dis, 2020, 22(2): e13250. DOI: 10.1111/tid.13250.
    [2]
    APOSTOLOPOULOU A, FISHMAN JA. The pathogenesis and diagnosis of pneumocystis jiroveci pneumonia[J]. J Fungi (Basel), 2022, 8(11): 1167. DOI: 10.3390/jof8111167.
    [3]
    HOSSEINI-MOGHADDAM SM, SHOKOOHI M, SINGH G, et al. Six-month risk of pneumocystis pneumonia following acute cellular rejection: a case-control study in solid organ transplant recipients[J]. Clin Transplant, 2021, 35(7): e14322. DOI: 10.1111/ctr.14322.
    [4]
    ZHANG F, CHEN J, HUANG H, et al. Application of metagenomic next-generation sequencing in the diagnosis and treatment guidance of pneumocystis jirovecii pneumonia in renal transplant recipients[J]. Eur J Clin Microbiol Infect Dis, 2021, 40(9): 1933-1942. DOI: 10.1007/s10096-021-04254-x.
    [5]
    XIE D, XU W, YOU J, et al. Clinical descriptive analysis of severe pneumocystis jirovecii pneumonia in renal transplantation recipients[J]. Bioengineered, 2021, 12(1): 1264-1272. DOI: 10.1080/21655979.2021.1911203.
    [6]
    XU J, YU Y, LV J, et al. Application of metagenomic next-generation sequencing to diagnose pneumocystis jirovecii pneumonia in kidney transplantation recipients[J]. Ann Transplant, 2021, 26: e931059. DOI: 10.12659/AOT.931059.
    [7]
    DE BOER MG, DE FIJTER JW, KROON FP. Outbreaks and clustering of pneumocystis pneumonia in kidney transplant recipients: a systematic review[J]. Med Mycol, 2011, 49(7): 673-680. DOI: 10.3109/13693786.2011.571294.
    [8]
    LE GAL S, TOUBAS D, TOTET A, et al. Pneumocystis infection outbreaks in organ transplantation units in France: a nation-wide survey[J]. Clin Infect Dis, 2020, 70(10): 2216-2220. DOI: 10.1093/cid/ciz901.
    [9]
    RICCI G, SANTOS DW, KOVACS JA, et al. Genetic diversity of pneumocystis jirovecii from a cluster of cases of pneumonia in renal transplant patients: cross-sectional study[J]. Mycoses, 2018, 61(11): 845-852. DOI: 10.1111/myc.12823.
    [10]
    MAITTE C, LETERRIER M, LE PAPE P, et al. Multilocus sequence typing of pneumocystis jirovecii from clinical samples: how many and which loci should be used?[J]. J Clin Microbiol, 2013, 51(9): 2843-2849. DOI: 10.1128/JCM.01073-13.
    [11]
    韩嘉静, 赵建康, 刘鑫梦, 等. 耶氏肺孢子菌肺炎临床特征分析[J]. 中华检验医学杂志, 2022, 45(9): 930-935. DOI: 10.3760/cma.j.cn114452-20211108-00689.

    HAN JJ, LIU JK, LIU XM, et al. Clinical features of pneumocystis jirovecii pneumonia[J]. Chin J Lab Med, 2022, 45(9): 930-935. DOI: 10.3760/cma.j.cn114452-20211108-00689.
    [12]
    薛婷, 杜伟勤. 耶氏肺孢子菌基因分型研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(6): 842-847. DOI: 10.12140/j.issn.1000-7423.2021.06.018.

    XUE T, DU WQ. Progress in genotyping of pneumocystis jirovecii[J]. Chin J Parasitol Parasit Dis, 2021, 39(6): 842-847. DOI: 10.12140/j.issn.1000-7423.2021.06.018.
    [13]
    孟静, 李光才, 肖建生, 等. 不同免疫状态下卡氏肺孢子菌肺炎临床特征的差异性分析[J]. 华中科技大学学报(医学版), 2021, 50(2): 225-229. DOI: 10.3870/j.issn.1672-0741.2021.02.016.

    MENG J, LI GC, XIAO JS, et al. Difference analysis of the clinical features of pneumocystis carinii pneumonia under different immune status[J]. Acta Med Univ Sci Technol Huazhong, 2021, 50(2): 225-229. DOI: 10.3870/j.issn.1672-0741.2021.02.016.
    [14]
    王明明, 杨学敏. 肾移植术后患者肺孢子菌肺炎临床特征分析[J]. 临床肺科杂志, 2020, 25(9): 1355-1358. DOI: 10.3969/j.issn.1009-6663.2020.09.014.

    WANG MM, YANG XM. Clinical characteristics of pneumocystis pneumonia in patients after renal transplantation[J]. J Clin Pulm Med, 2020, 25(9): 1355-1358. DOI: 10.3969/j.issn.1009-6663.2020.09.014.
    [15]
    TASAKA S. Recent advances in the diagnosis and management of pneumocystis pneumonia[J]. Tuberc Respir Dis (Seoul), 2020, 83(2): 132-140. DOI: 10.4046/trd.2020.0015.
    [16]
    HAMMARSTRÖM H, GRANKVIST A, BROMAN I, et al. Serum-based diagnosis of pneumocystis pneumonia by detection of pneumocystis jirovecii DNA and 1, 3-β-D-glucan in HIV-infected patients: a retrospective case control study[J]. BMC Infect Dis, 2019, 19(1): 658. DOI: 10.1186/s12879-019-4289-4.
    [17]
    GUEGAN H, ROBERT-GANGNEUX F. Molecular diagnosis of pneumocystis pneumonia in immunocompromised patients[J]. Curr Opin Infect Dis, 2019, 32(4): 314-321. DOI: 10.1097/QCO.0000000000000559.
    [18]
    ZHAN Y, GAO X, LI S, et al. Development and evaluation of rapid and accurate CRISPR/Cas13-based RNA diagnostics for pneumocystis jirovecii pneumonia[J]. Front Cell Infect Microbiol, 2022, 12: 904485. DOI: 10.3389/fcimb.2022.904485.
    [19]
    WANG J, HAN Y, FENG J. Metagenomic next-generation sequencing for mixed pulmonary infection diagnosis[J]. BMC Pulm Med, 2019, 19(1): 252. DOI: 10.1186/s12890-019-1022-4.
    [20]
    LU X, ZHANG J, MA W, et al. Pneumocystis jirovecii pneumonia diagnosis via metagenomic next-generation sequencing[J]. Front Med (Lausanne), 2022, 9: 812005. DOI: 10.3389/fmed.2022.812005.
    [21]
    冯玲, 熊佳丽, 易荣, 等. 宏基因组二代测序在肺部感染诊治的临床价值[J]. 临床肺科杂志, 2021, 26(12): 1834-1838. DOI: 10.3969/j.issn.1009-6663.2021.12.011.

    FENG L, XIONG JL, YI R, et al. Clinical value of metagenomic next-generation sequencing in diagnosis and treatment of pulmonary infection[J]. J Clin Pulm Med, 2021, 26(12): 1834-1838. DOI: 10.3969/j.issn.1009-6663.2021.12.011.
    [22]
    沈轶, 潘雁, 尹成胜, 等. 二代测序诊断肺移植后耶氏肺孢子菌肺炎二例并文献复习[J]. 中国呼吸与危重监护杂志, 2021, 20(7): 479-486. DOI: 10.7507/1671-6205.202104007.

    SHEN Y, PAN Y, YIN CS, et al. Pneumocystis jirovecii pneumonia diagnosed by next-genetation sequencing after lung transplantation: case report and literature review[J]. Chin J Respir Crit Care Med, 2021, 20(7): 479-486. DOI: 10.7507/1671-6205.202104007.
    [23]
    张彩霞, 刘新年, 杜川, 等. mNGS技术和血清G试验在判断耶氏肺孢子菌感染与定植中的价值及二者相关性研究[J]. 中国全科医学, 2023, 26(11): 1355-1360. DOI: 10.12114/j.issn.1007-9572.2022.0594.

    ZHANG CX, LIU XN, DU C, et al. mNGS and serum G test in distinguishing between pneumocystis jirovecii colonization and infection: value comparison and correlation analysis[J]. Chin Gen Pract, 2023, 26(11): 1355-1360. DOI: 10.12114/j.issn.1007-9572.2022.0594.
    [24]
    LIU L, YUAN M, SHI Y, et al. Clinical performance of BAL metagenomic next-generation sequence and serum (1, 3)-β-D-glucan for differential diagnosis of pneumocystis jirovecii pneumonia and pneumocystis jirovecii colonization[J]. Front Cell Infect Microbiol, 2021, 11: 784236. DOI: 10.3389/fcimb.2021.784236.
    [25]
    BATEMAN M, OLADELE R, KOLLS JK. Diagnosing pneumocystis jirovecii pneumonia: a review of current methods and novel approaches[J]. Med Mycol, 2020, 58(8): 1015-1028. DOI: 10.1093/mmy/myaa024.
    [26]
    LEE G, KOO TY, KIM HW, et al. Comparison of early and late pneumocystis jirovecii pneumonia in kidney transplant patients: the Korean Organ Transplantation Registry (KOTRY) study[J]. Sci Rep, 2022, 12(1): 10682. DOI: 10.1038/s41598-022-14580-5.
    [27]
    KUMAR D, GOURISHANKAR S, MUELLER T, et al. pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient[J]. Transpl Infect Dis, 2009, 11(2): 167-170. DOI: 10.1111/j.1399-3062.2008.00345.x.
    [28]
    PERRIER Q, PORTAIS A, TERREC F, et al. A case of pneumocystis jirovecii pneumonia under belatacept and everolimus: benefit-risk balance between renal allograft function and infection[J]. Case Rep Nephrol Dial, 2021, 11(1): 10-15. DOI: 10.1159/000510842.
    [29]
    AZAR MM, COHEN E, MA L, et al. Genetic and epidemiologic analyses of an outbreak of pneumocystis jirovecii pneumonia among kidney transplant recipients in the United States[J]. Clin Infect Dis, 2022, 74(4): 639-647. DOI: 10.1093/cid/ciab474.
    [30]
    KAMINSKI H, BELLIERE J, BURGUET L, et al. Identification of predictive markers and outcomes of late-onset pneumocystis jirovecii pneumonia in kidney transplant recipients[J]. Clin Infect Dis, 2021, 73(7): e1456-e1463. DOI: 10.1093/cid/ciaa1611.
    [31]
    ZOU J, QIU T, ZHOU J, et al. Clinical manifestations and outcomes of renal transplantation patients with pneumocystis jirovecii pneumonia and cytomegalovirus co-infection[J]. Front Med (Lausanne), 2022, 9: 860644. DOI: 10.3389/fmed.2022.860644.
    [32]
    LEE S, PARK Y, KIM SG, et al. The impact of cytomegalovirus infection on clinical severity and outcomes in kidney transplant recipients with pneumocystis jirovecii pneumonia[J]. Microbiol Immunol, 2020, 64(5): 356-365. DOI: 10.1111/1348-0421.12778.
    [33]
    DUAN J, GAO J, LIU Q, et al. Characteristics and prognostic factors of non-HIV immunocompromised patients with pneumocystis pneumonia diagnosed by metagenomics next-generation sequencing[J]. Front Med (Lausanne), 2022, 9: 812698. DOI: 10.3389/fmed.2022.812698.
    [34]
    MEYER AMJ, SIDLER D, HIRZEL C, et al. Distinct clinical and laboratory patterns of pneumocystis jirovecii pneumonia in renal transplant recipients[J]. J Fungi (Basel), 2021, 7(12): 1072. DOI: 10.3390/jof7121072.
    [35]
    LING J, ANDERSON T, WARREN S, et al. Hypercalcaemia preceding diagnosis of pneumocystis jirovecii pneumonia in renal transplant recipients[J]. Clin Kidney J, 2017, 10(6): 845-851. DOI: 10.1093/ckj/sfx044.
    [36]
    MARTIN SI, FISHMAN JA, AST Infectious Diseases Community of Practice. pneumocystis pneumonia in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4): 272-279. DOI: 10.1111/ajt.12119.
    [37]
    段艳, 徐媛, 杨长青, 等. 复方磺胺甲唑联合卡泊芬净治疗耶氏肺孢子菌肺炎疗效与安全性的meta分析[J]. 中国真菌学杂志, 2023, 18(1): 1-7. DOI: 10.3969/j.issn.1673-3827.2023.01.001.

    DUAN Y, XU Y, YANG CQ, et al. Meta-analysis of trimethoprim-sulfamethoxazole combined with caspofungin in the treatment of pneumocys-tis jirovecii pneumonia[J]. Chin J Mycol, 2023, 18(1): 1-7. DOI: 10.3969/j.issn.1673-3827.2023.01.001.
    [38]
    姚芳, 路敏, 孔妍, 等. 耶氏肺孢子虫肺炎患者复方磺胺甲唑剂量调整分析[J]. 中国临床药理学杂志, 2022, 38(3): 267-269. DOI: 10.13699/j.cnki.1001-6821.2022.03.017.

    YAO F, LU M, KONG Y, et al. Analysis of the dose adjustment of compound sulfamethoxazole in a patient with pneumocystis pneumonia[J]. Chin J Clin Pharm, 2022, 38(3): 267-269. DOI: 10.13699/j.cnki.1001-6821.2022.03.017.
    [39]
    TU GW, JU MJ, XU M, et al. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe pneumocystis jirovecii pneumonia in renal transplant recipients[J]. Nephrology (Carlton), 2013, 18(11): 736-742. DOI: 10.1111/nep.12133.PMID:24571744.
    [40]
    JI J, WANG Q, HUANG T, et al. Efficacy of low-dose trimethoprim/sulfamethoxazole for the treatment of pneumocystis jirovecii pneumonia in deceased donor kidney recipients[J]. Infect Drug Resist, 2021, 14: 4913-4920. DOI: 10.2147/IDR.S339622.
    [41]
    GU ZY, LIU WJ, HUANG DL, et al. Preliminary study on the combination effect of clindamycin and low dose trimethoprim-sulfamethoxazole on severe pneumocystis pneumonia after renal transplantation[J]. Front Med (Lausanne), 2022, 9: 827850. DOI: 10.3389/fmed.2022.827850.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (206) PDF downloads(71) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return